Does Kesimpta Carry Serious Risks?
Kesimpta (ofatumumab), a monoclonal antibody for relapsing multiple sclerosis (MS), has a boxed warning for progressive multifocal leukoencephalopathy (PML), a rare but fatal brain infection linked to JC virus reactivation. PML occurred in clinical trials and post-marketing reports, often in patients with prior immunosuppressant use.[1][2] The FDA approves it as safe for its indicated use when benefits outweigh risks, but it's not risk-free—serious infections, including hepatitis B reactivation, affected 1-2% of trial patients.[3]
What Side Effects Do Patients Report Most?
Common side effects (affecting >10% of users) include upper respiratory infections, injection reactions (redness, swelling), headache, and urinary tract infections. In ASCLEPIOS trials (Phase 3, n=1,882), injection-site reactions hit 20% initially but dropped over time; serious infections occurred in 2.5-3% vs. 1% on teriflunomide. Long-term data shows consistent rates through 4 years, with fatigue and COVID-19 infections also noted post-approval.[1][4]
How Does Kesimpta Compare Safety-Wise to Other MS Drugs?
| Drug | PML Risk | Infection Rate (Trials) | Liver Toxicity |
|------|----------|--------------------------|---------------|
| Kesimpta | Boxed warning; ~0.1% incidence | 50-60% (mostly mild) | Rare |
| Ocrevus (ocrelizumab) | Boxed warning; higher cumulative risk | 60% | Low |
| Mavenclad (cladribine) | No boxed; theoretical | 40-50% | Elevated (ALT >3x) |
| Tecfidera (dimethyl fumarate) | None | 40% | Common (20-30%) |
Kesimpta has lower PML risk than Ocrevus due to subcutaneous dosing and shorter B-cell depletion, but higher infection rates than oral options like Tecfidera. No direct head-to-head PML data exists.[2][5]
Who Should Avoid Kesimpta?
Contraindicated in active hepatitis B or PML history. Use caution in immunocompromised patients, those with JC virus antibodies (50-60% of adults), or active infections. Not studied in pregnancy (Category unknown); effective contraception required for 6 months after last dose. Liver monitoring needed for elevated enzymes.[1][3]
When Do Safety Concerns Arise Long-Term?
PML risk rises after 2+ years or with prior Rituxan/Tysabri use—monitor via MRI and symptoms like confusion. In 4-year extension trials, annualized relapse rate stayed low (0.1), but 1 PML case emerged. No new safety signals in real-world data from 2020-2023.[4][6]
Is Monitoring Enough to Make It Safe?
Monthly self-injections require HBV screening pre-treatment and periodic bloodwork. FDA post-marketing surveillance tracks rare events; EMA reports similar profile. Patient registries like PAN confirm tolerability, with 80-90% adherence at 2 years.[1][7]
[1]: FDA Kesimpta Label
[2]: Novartis ASCLEPIOS Results
[3]: Drugs.com Kesimpta Side Effects
[4]: 4-Year ASCLEPIOS Open-Label Extension
[5]: Ocrevus vs Kesimpta Comparison
[6]: PML Risk Assessment
[7]: PAN Patient Registry Data